Workflow
Logic
icon
Search documents
背靠祖国,港澳科创“振翅起飞”
Ren Min Ri Bao· 2025-05-05 21:58
科技创新是高质量发展的核心驱动力。自《粤港澳大湾区发展规划纲要》发布以来,大湾区科技创新建 设按下"加速键",香港、澳门与粤港澳大湾区内地城市珠联璧合,深化产学研协同创新,汇聚全球创新 资源,不断刷新科技创新的"成绩单"。 港澳科创事业的飞速发展,离不开中央的大力支持。国家"十四五"规划纲要明确提出支持香港建设国际 创新科技中心,多项中央惠港惠澳科技政策相继落地,为香港、澳门的科创发展提供坚实依托和强大底 气。从中央财政科研经费过境支持港澳科技发展,到多个国家级科学基金项目向港澳地区开放;从港澳 载荷专家首次入选国家预备航天员,到香港大学、澳门科技大学获得研究嫦娥月壤的宝贵机会……在发 展科技创新的道路上,中央一直是港澳最强大的后盾和支撑。而这也为港澳产业转型升级、拓展发展新 空间、保持长期繁荣稳定,注入了强劲动力。 走进香港数码港,浓厚的创新气息扑面而来。人工智能、区块链、金融科技……新兴产业初创公司不断 涌现、快速成长,尽显香港科创发展的澎湃活力。 澳门科创,同样好风正起。在中药质量研究、太空科学、健康科学等领域,澳门发展势头正好,高水平 科研成果不断涌现,"科创"成为澳门的崭新名片。 面对科技创新带来的 ...
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Globenewswire· 2025-05-02 00:14
Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trialFull results from the trial will be submitted for presentation at an upcoming medical conference in 2025 COPENHAGEN, Denmark; May 2, 2024 – Genmab A/S (Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for ...
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
Globenewswire· 2025-05-01 12:00
SAN FRANCISCO and BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will present at the Bank of America Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T. / 4:40 p.m. E.T. A live and archived webcast of the presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancing novel b ...
Top Founder-Run Company Stocks That Can Drive Solid Returns
ZACKS· 2025-04-30 18:55
Core Insights - Founder-led companies, while representing less than 5% of the S&P 500 index, contribute significantly to the market, accounting for nearly 15% of the total index's market capitalization, particularly in the technology sector [3][4]. Group 1: Founder-led Companies - Founders exhibit a unique passion and risk appetite, often leading to innovative and successful ventures that reflect their core values [2][5]. - Notable founder-led companies include NVIDIA, Amazon, Meta, Tesla, Berkshire Hathaway, and Netflix, which have redefined industries and created trillion-dollar valuations [3]. Group 2: Performance of Founder-led Companies - A Harvard Business Review study indicates that founder-led companies achieved a market-adjusted return of 12% over three years, contrasting with a negative 26% return for companies with professional CEOs [7]. - Current appealing stocks identified include Netflix, Intercontinental Exchange, and Affirm Holdings [7]. Group 3: Netflix - Netflix, co-founded by Reed Hastings, has a market capitalization of $387.7 billion and has transitioned from DVD rentals to a leading streaming service [9]. - The company is focusing on expanding its original content portfolio and has launched low-priced mobile plans in various countries to drive international growth [11]. - Netflix projects revenues between $43.5 billion and $44.5 billion for 2025, with an operating margin of 29% [13]. Group 4: Intercontinental Exchange (ICE) - ICE, founded by Jeffrey Sprecher, has a market capitalization of $95.6 billion and has reported record net revenues and earnings for 19 consecutive years [14]. - The company is well-positioned for growth due to the digitization of the U.S. residential mortgage industry and the integration of Ellie Mae into its operations [16]. Group 5: Affirm - Affirm, with a market capitalization of $16.3 billion, is a key player in the Buy Now Pay Later (BNPL) segment, collaborating with over 337,000 active merchant partners [18]. - The company aims for profitability starting in Q4 of fiscal 2025 and is planning international expansion into Australia and Western Europe [19].
BioAtla to Participate in the Citizens Life Sciences Conference
Globenewswire· 2025-04-30 12:00
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update and participate in one-on-one investor meetings at the Citizens Life Sciences Conference, to be held in New York, NY May 7-8, 2025. Format: Corporate update and one-on-one investor meetings ...
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
GlobeNewswire News Room· 2025-04-30 05:00
Ad Hoc Announcement Pursuant to Art. 53 LR Functional recovery following stroke relies on the formation of new or reactivation of existing neural connections. Accumulating evidence suggests that the mGlu5 receptor modulates brain plasticity and function. A paper published in BRAIN*, titled "Inhibiting metabotropic glutamate receptor 5 after stroke restores brain function and connectivity", showed that daily treatment with mGlu5 NAMs for 12 days, starting 2 or 10 days after stroke, restored lost somatosensor ...
Astronics Surges 32% in a Year: Should You Buy the Stock Now?
ZACKS· 2025-04-29 18:35
Core Viewpoint - Astronics Corporation (ATRO) has shown strong stock performance, with a 32.3% increase over the past year, outperforming both the Zacks Aerospace-Defense Equipment industry and the broader Zacks Aerospace sector [1][2]. Group 1: Stock Performance - ATRO's stock has outperformed the S&P 500's return of 8.3% during the same period [1]. - Other industry players like Leonardo DRS and Curtiss-Wright Corp. have also performed well, with stock increases of 67.5% and 31.7%, respectively [2]. Group 2: Drivers of Growth - Significant contracts, such as the U.S. Army Future Long Range Assault Aircraft contract, are expected to contribute approximately $60-$65 million in revenues over the next few years [4]. - A contract secured in April 2025 to supply the Frequency Converter Unit for NASA and Boeing's TTBW X-66 aircraft demonstrator will further support revenue growth [5]. - The company reported a solid 15% year-over-year sales increase in 2024, indicating strong operational performance [6]. Group 3: Financial Position - As of December 2024, ATRO had cash and cash equivalents of $18 million and no current debt, with long-term debt totaling $169 million [7]. - The company is positioned to invest in new product innovation, which is crucial for growth in the aerospace sector [7]. Group 4: Future Outlook - The Zacks Consensus Estimate predicts a 3.6% year-over-year growth in sales for 2025 and an 8.2% increase for 2026 [11]. - Earnings estimates show significant growth potential, with a projected year-over-year increase of 377.78% for the current quarter and 53.10% for the next year [13]. Group 5: Valuation - ATRO's forward 12-month price-to-earnings (P/E) ratio is 16.63X, which is below the peer group average of 23.42X, indicating a potentially attractive investment opportunity [14].
QuestMobile2025 全景生态流量春季报告:智能设备持续爆发,催动生态流量边界扩张!
QuestMobile· 2025-04-29 01:59
各位童鞋搭嘎猴啊,上周 "泛年轻人群营销洞察"看的怎么样?有童鞋在后台留言:"各家都 说取消大小周、取消996,怎么说呢,反正,恍恍惚惚又到五月了,期待五一长 假……"O(∩_∩)O哈哈~兄嘚别这么含蓄,有啥想说的直抒胸臆就行,毕竟,俺们程序猿、攻 城狮们啥大风大浪没见过?(#^ . ^#) 言归正传,今天就给大家分享一下2025年全景生态流量春季报告。Qu e s tMobi l e数据显 示,截止到3月份,全网用户规模已经达到12.59亿,同比增长了2.2%,,智能设备、数字 阅读、移动视频、教育学习成为月活跃用户规模增速Top4的赛道,同比增长分别达到 9.8%、9.3%、6%、5.1%。 这当中,智能设备迎来了爆发时刻:智能家居、智能穿戴及智能汽车APP行业的月活跃用户 规模同比分别增长了14.6%、14.8%、33.2%,走出了移动互联网走向成熟之后最劲爆的 一轮增长表现,尤其是智能汽车APP,3月份月活用户已经达到0.86亿,距离破亿大关仅一 步之遥! 同时,智能设备行业以APP为中枢,串联诸多品类形成智能生态,实现销售与用户齐飞的景 象,3月份,米家、华为运动健康、萤石云视频应用去重用户规模分别 ...
Senti Biosciences (SNTI) Update / Briefing Transcript
2025-04-28 22:19
Summary of Senti Biosciences Senti-two zero two Clinical Update Conference Call Company and Industry - **Company**: Senti Biosciences - **Industry**: Biotechnology, specifically focused on cell therapy for hematological malignancies, particularly Acute Myeloid Leukemia (AML) Core Points and Arguments 1. **Introduction of Senti-two zero two**: Senti Biosciences is developing SENTI-two zero two, a logic gated CAR NK cell therapy targeting relapsed/refractory AML and related hematological cancers, with promising preliminary results from a Phase one trial [6][7][40]. 2. **Mechanism of Action**: The therapy utilizes a unique logic gate technology that allows for precise targeting of cancer cells while sparing healthy cells, addressing the challenge of heterogeneous cancer cell populations [8][10][14]. 3. **Patient Demographics**: AML affects approximately 21,000 patients annually in the U.S., with a high relapse rate and poor prognosis, highlighting the urgent need for effective therapies [11][12]. 4. **Trial Design**: The Phase one trial is a multi-center, open-label study enrolling adult patients aged 18-75 with relapsed/refractory AML, focusing on safety, maximum tolerated dose (MTD), and efficacy [19][20]. 5. **Dosing and Administration**: The trial evaluates two dose levels of 1 billion and 1.5 billion CAR NK cells, administered in either three or five doses following lymphodepletion [22][23]. 6. **Safety Profile**: Preliminary safety data indicate that SENTI-two zero two is well tolerated, with no dose-limiting toxicities reported and adverse events primarily being hematologic in nature [26][29][40]. 7. **Efficacy Results**: Five out of seven patients achieved an overall response rate (ORR), with four achieving complete remission (CR), indicating promising efficacy in a heavily treated patient population [30][31][40]. 8. **Durability of Response**: All CR patients were minimal residual disease (MRD) negative, with ongoing responses and a median duration of response not yet reached [31][34][41]. 9. **Future Directions**: The company plans to expand the trial to include more patients and potentially explore other malignancies expressing CD33 or FLT3, such as MDS [49][62]. Other Important but Possibly Overlooked Content 1. **Logic Gate Technology**: The logic gate mechanism allows for the recognition of multiple cancer antigens, enhancing the therapy's ability to target diverse cancer cell populations [9][10]. 2. **Patient Characteristics**: The trial population had multiple adverse prognostic factors, including rapid failure of prior therapies and adverse genetic characteristics, underscoring the high unmet need in this patient group [24][25][34]. 3. **Comparison with Existing Therapies**: Current standard care for relapsed/refractory AML shows low response rates (15-25% for CR), emphasizing the need for innovative therapies like SENTI-two zero two [12][65]. 4. **Potential for Outpatient Use**: Given the favorable safety profile of NK cells, there are plans to develop SENTI-two zero two for outpatient administration [50]. 5. **Broader Applications**: The technology has potential applications beyond AML, including solid tumors, which could significantly expand its therapeutic reach [60][61]. This summary encapsulates the key points discussed during the conference call, highlighting the innovative approach of Senti Biosciences in addressing a critical need in cancer treatment.
Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
Globenewswire· 2025-04-28 11:00
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified 5 of 7 best overall response evaluable patients achieved ORR (3 CR, 1 CRh and 1 morphologic leukemia-free state) across all dose cohorts, including 1 CR and 1 CRh in 3 patients in preliminary RP2D cohort 4 of 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of ca ...